@article{5f9a866fe33e402482c5fad8174096cb,
title = "New treatment options for the management of multiple myeloma",
abstract = "Multiple myeloma (MM) is a complex disease characterized by considerable genetic heterogeneity. The updated NCCN Guidelines for MM have added new “preferred” regimens for transplant and nontransplant candidates, and have moved some formerly “preferred” regimens to the “other” category. Supportive care has improved outcomes for patients, and new treatments in combination have extended survival for patients with MM. Novel agents on the horizon are poised to raise the bar even further.",
author = "Kumar, {Shaji K.}",
note = "Funding Information: Presented by Shaji K. Kumar, MD, Division of Hematology, Mayo Clinic Cancer Center, Rochester, Minnesota. Dr. Kumar has disclosed that he receives grant/research support from Abbott Laboratories, Amgen Inc.; Celgene Corporation; Janssen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S.; and Takeda Pharmaceuticals North America, Inc. He serves as a scientific advisor for Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, GlycoMimetics, Janssen Pharmaceutica Products, LP, sanofi-aventis U.S., and Takeda Pharmaceuticals North America, Inc.; and has received consulting fees/honoraria from Kesios Therapeutics, NOXXON Pharma AG, and SkylineDx. Correspondence: Shaji K. Kumar, MD, Division of Hematology, 200 First Street SW, Rochester, MN 55905. E-mail: kumar.shaji@mayo.edu Publisher Copyright: {\textcopyright} JNCCN.",
year = "2017",
month = may,
doi = "10.6004/jnccn.2017.0080",
language = "English (US)",
volume = "15",
pages = "709--712",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5S",
}